Al Sharaby Afrah, Abugoukh Tahani M, Ahmed Wefag, Ahmed Samah, Elshaikh Abeer O
Internal Medicine, Michigan State University, San Francisco, USA.
Medicine, Shendi University, Cedar Rapids, USA.
Cureus. 2022 Aug 2;14(8):e27624. doi: 10.7759/cureus.27624. eCollection 2022 Aug.
Clostridium difficile is a bacterium that affects the gastrointestinal tract and is the leading cause of antibiotic-associated diarrhea. A wide range of probiotics has been studied and used to prevent or treat Clostridium difficile-associated diarrhea (CDAD). Probiotics are microorganisms with unique characteristics that suppress dangerous gut bacteria through several mechanisms. The main objective of this study is to evaluate the efficacy and safety of probiotics in the prevention of CDAD. In this literature review, we searched PubMed and Google Scholar databases to gather related articles depending on predetermined eligibility criteria and found 13 papers of different study designs. We found that probiotics have promising effects in preventing CDAD. Additionally, they were safe and well-tolerated. Further randomized clinical trials with larger sample sizes and various patient groups are needed to better understand the advantages of probiotics and recommend the best dose and duration of probiotic treatment.
艰难梭菌是一种影响胃肠道的细菌,是抗生素相关性腹泻的主要病因。人们已经研究了多种益生菌并将其用于预防或治疗艰难梭菌相关性腹泻(CDAD)。益生菌是具有独特特性的微生物,可通过多种机制抑制有害肠道细菌。本研究的主要目的是评估益生菌预防CDAD的疗效和安全性。在这篇文献综述中,我们根据预先确定的入选标准,在PubMed和谷歌学术数据库中搜索以收集相关文章,共找到13篇不同研究设计的论文。我们发现益生菌在预防CDAD方面具有显著效果。此外,它们安全且耐受性良好。需要进一步开展更大样本量和针对不同患者群体的随机临床试验,以更好地了解益生菌的优势,并推荐最佳的益生菌治疗剂量和疗程。